British Columbia Starts Biosimilar Switching Program

The Canadian province of British Columbia has announced a biosimilar switching program for etanercept, infliximab and insulin glargine that will see patients using original biologics switched to biosimilars within six months.

Canada
British Columbia is leading the way on biosimilar switching in Canada • Source: Shutterstock

A biosimilar switching program announced by the government of the Canadian province of British Columbia that will see patients using a brand biologic switched to a biosimilar within six months has been warmly received by industry.

The government of BC said the program – instigated following a broad stakeholder consultation – was aimed at “improving the...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Biosimilars

More from Products

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

    We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

  • Biocon And Teva Sign Up To Biosimilars Forum

    Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.